Charles Schwab’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-617,561
| Closed | -$13.2M | – | 3469 |
|
|
2026
Q1 | $13.2M | Sell |
617,561
-16,133
| -3% | -$227K | ﹤0.01% | 1969 |
|
|
2025
Q4 | $5.91M | Buy |
633,694
+23,630
| +4% | +$197K | ﹤0.01% | 2372 |
|
|
2025
Q3 | $4.3M | Buy |
610,064
+31,301
| +5% | +$215K | ﹤0.01% | 2504 |
|
|
2025
Q2 | $3.76M | Buy |
578,763
+50,615
| +10% | +$348K | ﹤0.01% | 2456 |
|
|
2025
Q1 | $4.19M | Sell |
528,148
-7,353
| -1% | -$79.2K | ﹤0.01% | 2342 |
|
|
2024
Q4 | $6.78M | Buy |
535,501
+28,053
| +6% | +$390K | ﹤0.01% | 2189 |
|
|
2024
Q3 | $7.07M | Buy |
507,448
+64,700
| +15% | +$923K | ﹤0.01% | 2193 |
|
|
2024
Q2 | $6.1M | Sell |
442,748
-14,904
| -3% | -$218K | ﹤0.01% | 2268 |
|
|
2024
Q1 | $7.56M | Buy |
457,652
+4,718
| +1% | +$70.6K | ﹤0.01% | 2125 |
|
|
2023
Q4 | $6.61M | Buy |
452,934
+5,796
| +1% | +$70.3K | ﹤0.01% | 2196 |
|
|
2023
Q3 | $5.49M | Buy |
447,138
+125,050
| +39% | +$1.63M | ﹤0.01% | 2210 |
|
|
2023
Q2 | $3.85M | Buy |
322,088
+119,421
| +59% | +$1.56M | ﹤0.01% | 2338 |
|
|
2023
Q1 | $2.71M | Sell |
202,667
-1,238
| -0.6% | -$24.2K | ﹤0.01% | 2441 |
|
|
2022
Q4 | $4.39M | Buy |
203,905
+4,953
| +2% | +$102K | ﹤0.01% | 2284 |
|
|
2022
Q3 | $3.99M | Buy |
198,952
+45,909
| +30% | +$976K | ﹤0.01% | 2339 |
|
|
2022
Q2 | $2.74M | Buy |
153,043
+49,009
| +47% | +$506K | ﹤0.01% | 2461 |
|
|
2022
Q1 | $1.03M | Buy |
104,034
+27,866
| +37% | +$368K | ﹤0.01% | 2836 |
|
|
2021
Q4 | $1.28M | Buy |
76,168
+942
| +1% | +$19.4K | ﹤0.01% | 2821 |
|
|
2021
Q3 | $1.79M | Buy |
+75,226
| New | +$1.8M | ﹤0.01% | 2724 |
|
Other funds holding DAWN
Charles Schwab's DAWN Position: Q2 2026 in Review
Charles Schwab sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 617,561 shares — an estimated $13.2M sold.
Charles Schwab first reported a position in DAWN in Q3 2021 and held it in 19 quarters. The position peaked at $13.2M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Charles Schwab reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Charles Schwab sold 617,561 Day One Biopharmaceuticals shares in Q2 2026, an estimated $13.2M.
- Charles Schwab first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 19 quarters.
- Charles Schwab's Day One Biopharmaceuticals position peaked at $13.2M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.